VB19055 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chine
The purpose of this study is to evaluate the safety,tolerability,pharmacokinetics and pharmacodynamics of VB19055 in the healthy Chinese population.
| Condition(s) | Hypertension |
|---|---|
| Status | Recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Summary | The purpose of this study is to evaluate the safety,tolerability,pharmacokinetics and pharmacodynamics of VB19055 in the healthy Chinese population. |
| Who can participate | Inclusion Criteria: 1. Voluntarily participate in clinical trials, understand the nature of the study and any risks involved in participation, sign an informed consent form, and be willing to comply with the requirements specified in the protocol; 2. Aged between 18 and 50 years (inclusive), healthy volunteers; 3. Body mass index (BMI) between 18-26 kg/m² (inclusive), with minimum weight requirements of 50 kg (inclusive) for males and 45 kg (inclusive) for females; 4. In generally good health, as determined by the investigator based on medical history, surgical history, complete physical examination, vital signs measurements, laboratory tests, 12-lead electrocardiogram (ECG), and chest X-ray results, with no evidence of clinical disease and confirmed to be healthy; 5. For females of childb |
| Ages | 18 Years to 50 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. |
| Locations | Hangzhou, China; Shanghai, China |
| Start date | 2025-10-05 |
| NCT ID | NCT07254481 |
| Official listing | https://clinicaltrials.gov/study/NCT07254481 |